prestige consumer healthcare inc. - PBH

PBH

Close Chg Chg %
65.30 -0.64 -0.98%

Closed Market

64.66

-0.64 (0.98%)

Volume: 258.78K

Last Updated:

Jan 13, 2026, 3:59 PM EDT

Company Overview: prestige consumer healthcare inc. - PBH

PBH Key Data

Open

$65.90

Day Range

64.10 - 65.90

52 Week Range

57.25 - 90.04

Market Cap

$3.14B

Shares Outstanding

48.08M

Public Float

47.37M

Beta

0.40

Rev. Per Employee

N/A

P/E Ratio

15.92

EPS

$4.06

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

364.54K

 

PBH Performance

1 Week
 
0.83%
 
1 Month
 
5.31%
 
3 Months
 
4.20%
 
1 Year
 
-17.66%
 
5 Years
 
72.44%
 

PBH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About prestige consumer healthcare inc. - PBH

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the North American OTC Healthcare and International OTC Healthcare segments. The North American OTC Healthcare segment consists of BC and Goody's, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fleet, Gaviscon, Luden's, Monistat, Nix, Summer's Eve. The International OTC Healthcare segment includes Fess and Hydralite. The company was founded in 1996 and is headquartered in Tarrytown, NY.

PBH At a Glance

Prestige Consumer Healthcare, Inc.
660 White Plains Road
Tarrytown, New York 10591
Phone 1-914-524-6800 Revenue 1.14B
Industry Pharmaceuticals: Major Net Income 214.61M
Sector Health Technology 2025 Sales Growth 1.102%
Fiscal Year-end 03 / 2026 Employees 600
View SEC Filings

PBH Valuation

P/E Current 15.918
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 20.062
Price to Sales Ratio 3.784
Price to Book Ratio 2.32
Price to Cash Flow Ratio 17.12
Enterprise Value to EBITDA 13.842
Enterprise Value to Sales 4.616
Total Debt to Enterprise Value 0.199

PBH Efficiency

Revenue/Employee 1,896,270.00
Income Per Employee 357,675.00
Receivables Turnover 5.856
Total Asset Turnover 0.334

PBH Liquidity

Current Ratio 4.205
Quick Ratio 2.819
Cash Ratio 0.918

PBH Profitability

Gross Margin 53.893
Operating Margin 30.695
Pretax Margin 24.978
Net Margin 18.862
Return on Assets 6.30
Return on Equity 12.298
Return on Total Capital 7.454
Return on Invested Capital 7.584

PBH Capital Structure

Total Debt to Total Equity 56.911
Total Debt to Total Capital 36.269
Total Debt to Total Assets 30.22
Long-Term Debt to Equity 56.445
Long-Term Debt to Total Capital 35.973
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Prestige Consumer Healthcare Inc. - PBH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.09B 1.13B 1.13B 1.14B
Sales Growth
+15.21% +3.76% -0.21% +1.10%
Cost of Goods Sold (COGS) incl D&A
491.03M 527.51M 523.46M 524.59M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
38.80M 38.94M 30.68M 30.17M
Depreciation
17.30M 16.67M 10.89M 11.91M
Amortization of Intangibles
21.50M 22.27M 19.78M 18.26M
COGS Growth
+16.96% +7.43% -0.77% +0.22%
Gross Income
595.78M 600.22M 601.90M 613.17M
Gross Income Growth
+13.80% +0.75% +0.28% +1.87%
Gross Profit Margin
+54.82% +53.22% +53.48% +53.89%
2022 2023 2024 2025 5-year trend
SG&A Expense
265.86M 252.41M 259.47M 263.93M
Research & Development
- - - -
-
Other SG&A
265.86M 252.41M 259.47M 263.93M
SGA Growth
+17.57% -5.06% +2.79% +1.72%
Other Operating Expense
- - - -
-
Unusual Expense
- 2.12M 370.22M 12.47M
EBIT after Unusual Expense
327.80M (22.41M) 342.43M 336.77M
Non Operating Income/Expense
(3.48M) (2.34M) 756.00K (4.95M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
61.86M 69.16M 67.16M 47.63M
Interest Expense Growth
-20.25% +11.81% -2.90% -29.08%
Gross Interest Expense
61.86M 69.16M 67.16M 47.63M
Interest Capitalized
- - - -
-
Pretax Income
262.46M (93.92M) 276.02M 284.19M
Pretax Income Growth
+28.58% -135.78% +393.91% +2.96%
Pretax Margin
+24.15% -8.33% +24.53% +24.98%
Income Tax
57.08M (11.61M) 66.69M 69.58M
Income Tax - Current - Domestic
38.41M 37.20M 31.96M 40.07M
Income Tax - Current - Foreign
8.71M 11.96M 11.65M 11.09M
Income Tax - Deferred - Domestic
10.68M (60.67M) 23.62M 17.45M
Income Tax - Deferred - Foreign
(715.00K) (90.00K) (546.00K) 975.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
205.38M (82.31M) 209.34M 214.60M
Minority Interest Expense
- - - -
-
Net Income
205.38M (82.31M) 209.34M 214.60M
Net Income Growth
+24.71% -140.07% +354.34% +2.52%
Net Margin Growth
+18.90% -7.30% +18.60% +18.86%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
205.38M (82.31M) 209.34M 214.60M
Preferred Dividends
- - - -
-
Net Income Available to Common
205.38M (82.31M) 209.34M 214.60M
EPS (Basic)
4.0864 -1.6498 4.2072 4.3183
EPS (Basic) Growth
+24.59% -140.37% +355.01% +2.64%
Basic Shares Outstanding
50.26M 49.89M 49.76M 49.70M
EPS (Diluted)
4.0396 -1.6498 4.1719 4.2852
EPS (Diluted) Growth
+24.13% -140.84% +352.87% +2.72%
Diluted Shares Outstanding
50.84M 49.89M 50.18M 50.08M
EBITDA
368.72M 386.74M 373.10M 379.41M
EBITDA Growth
+10.18% +4.89% -3.53% +1.69%
EBITDA Margin
+33.93% +34.29% +33.15% +33.35%

Snapshot

Average Recommendation BUY Average Target Price 78.20
Number of Ratings 7 Current Quarters Estimate 1.407
FY Report Date 03 / 2026 Current Year's Estimate 4.559
Last Quarter’s Earnings 1.14 Median PE on CY Estimate N/A
Year Ago Earnings 4.52 Next Fiscal Year Estimate 4.861
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 2 7 7
Mean Estimate 1.41 1.00 4.56 4.86
High Estimates 1.44 1.00 4.58 4.91
Low Estimate 1.39 0.99 4.55 4.80
Coefficient of Variance 1.40 0.51 0.27 0.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Prestige Consumer Healthcare Inc. - PBH

Date Name Shares Transaction Value
Mar 6, 2025 Mary Beth Fritz SVP Quality & Regulatory 25,132 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $44.33 per share 1,114,101.56
Mar 6, 2025 Mary Beth Fritz SVP Quality & Regulatory 18,835 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.39 per share 1,608,320.65
Mar 6, 2025 Mary Beth Fritz SVP Quality & Regulatory N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Prestige Consumer Healthcare Inc. in the News